ATC Group: L03AB11 Peginterferon alfa-2a

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L03AB11 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L03 Immunostimulants
3 L03A Immunostimulants
4 L03AB Interferons
5 L03AB11 Peginterferon alfa-2a

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 26 ug

Active ingredients in L03AB11

Active Ingredient Description
Peginterferon alpha-2a

Peginterferon alpha-2a is a pegylated interferon alfa-2a that possesses the in vitro antiviral and antiproliferative activities that are characteristic of interferon alfa-2a. Peginterferon alpha-2a is indicated for the treatment of hepatitis B and C.

Related product monographs

Title Information Source Document Type  
PEGASYS Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Cyprus (CY)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.